Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis
MedinCell (Paris:MEDCL):
No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication
The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile
It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources
The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal
MedinCell is making this review available immediately at www.medincell.com/ivermectin Publications over the last few months show a significant body of clinical data and scientific knowledge supporting the efficacy of ivermectin at therapeutic dose against Covid-19, for both curative and prophylactic purpose , says Christophe Douat, CEO of MedinCell.